semaglutide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Glucagon-like Peptide (GLP) analogues 5267 910463-68-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • semaglutide
  • NNC 0113-0217
  • ozempic
Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.
  • Molecular weight: 4113.64
  • Formula: C187H291N45O59
  • CLOGP:
  • LIPINSKI: None
  • HAC: 104
  • HDO: 57
  • TPSA: 1646.18
  • ALOGS:
  • ROTB: 149

Drug dosage:

DoseUnitRoute
0.11 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 8, 2018 EMA Novo Nordisk A/S
March 23, 2018 PMDA Novo Nordisk Pharma Ltd
Dec. 5, 2017 FDA NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nausea 245.22 52.60 95 367 112094 2245529
Vomiting 173.59 52.60 66 396 71536 2286087
Pancreatitis 154.65 52.60 37 425 8042 2349581
Diabetic ketoacidosis 66.18 52.60 16 446 3548 2354075

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nausea 260.27 50.57 93 384 51103 1695201
Vomiting 186.83 50.57 68 409 38247 1708057
Diarrhoea 150.61 50.57 64 413 53788 1692516
Pancreatitis 124.99 50.57 34 443 7153 1739151
Weight decreased 72.54 50.57 30 447 22723 1723581
Inappropriate schedule of product administration 57.93 50.57 19 458 7440 1738864
Eructation 53.41 50.57 11 466 682 1745622

Pharmacologic Action:

SourceCodeDescription
ATC A10BJ06 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Glucagon-like peptide-1 (GLP-1) analogues
FDA EPC N0000178480 GLP-1 Receptor Agonist
FDA CS M0160181 Glucagon-Like Peptide 1
FDA MoA N0000020058 Glucagon-like Peptide-1 (GLP-1) Agonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.23 acidic
pKa2 3.31 acidic
pKa3 3.71 acidic
pKa4 3.97 acidic
pKa5 4.22 acidic
pKa6 4.53 acidic
pKa7 4.76 acidic
pKa8 9.65 acidic
pKa9 12.06 acidic
pKa10 12.28 acidic
pKa11 12.41 acidic
pKa12 12.5 acidic
pKa13 12.63 acidic
pKa14 12.76 acidic
pKa15 12.95 acidic
pKa16 12.98 acidic
pKa17 13.11 acidic
pKa18 13.18 acidic
pKa19 13.24 acidic
pKa20 13.3 acidic
pKa21 13.4 acidic
pKa22 13.51 acidic
pKa23 13.61 acidic
pKa24 13.66 acidic
pKa25 13.73 acidic
pKa26 13.77 acidic
pKa27 13.83 acidic
pKa28 13.87 acidic
pKa29 13.94 acidic
pKa30 11.05 Basic
pKa31 10.45 Basic
pKa32 7.88 Basic
pKa33 5.98 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
2MG/1.5ML (1.34MG/ML) OZEMPIC NOVO N209637 Dec. 5, 2017 RX SOLUTION SUBCUTANEOUS 8536122 March 20, 2026 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
14MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 8536122 March 20, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 8536122 March 20, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 8536122 March 20, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
2MG/1.5ML (1.34MG/ML) OZEMPIC NOVO N209637 Dec. 5, 2017 RX SOLUTION SUBCUTANEOUS 8129343 Jan. 29, 2029 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
14MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 8129343 Jan. 29, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 8129343 Jan. 29, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 8129343 Jan. 29, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
14MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 9278123 Dec. 16, 2031 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 9278123 Dec. 16, 2031 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 9278123 Dec. 16, 2031 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
2MG/1.5ML (1.34MG/ML) OZEMPIC NOVO N209637 Dec. 5, 2017 RX SOLUTION SUBCUTANEOUS 10335462 June 21, 2033 A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
14MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 10278923 May 2, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 10278923 May 2, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 10278923 May 2, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
14MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL Sept. 20, 2022 NEW PRODUCT
3MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL Sept. 20, 2022 NEW PRODUCT
7MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL Sept. 20, 2022 NEW PRODUCT
2MG/1.5ML (1.34MG/ML) OZEMPIC NOVO N209637 Dec. 5, 2017 RX SOLUTION SUBCUTANEOUS Dec. 5, 2022 NEW CHEMICAL ENTITY
14MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL Dec. 5, 2022 NEW CHEMICAL ENTITY
3MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL Dec. 5, 2022 NEW CHEMICAL ENTITY
7MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL Dec. 5, 2022 NEW CHEMICAL ENTITY
2MG/1.5ML (1.34MG/ML) OZEMPIC NOVO N209637 Dec. 5, 2017 RX SOLUTION SUBCUTANEOUS Jan. 16, 2023 REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
4MG/3ML (1.34MG/ML) OZEMPIC NOVO N209637 April 9, 2019 RX SOLUTION SUBCUTANEOUS Jan. 16, 2023 REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
14MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL Jan. 16, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
3MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL Jan. 16, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
7MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL Jan. 16, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucagon-like peptide 1 receptor GPCR AGONIST IC50 9.42 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
53AXN4NNHX UNII
9113 INN_ID
D10025 KEGG_DRUG
DB13928 DRUGBANK_ID
CHEMBL2108724 ChEMBL_ID
56843331 PUBCHEM_CID
9724 IUPHAR_LIGAND_ID
C000591245 MESH_SUPPLEMENTAL_RECORD_UI
764284009 SNOMEDCT_US
764283003 SNOMEDCT_US
1991302 RXNORM
017424 NDDF
33346 MMSL
d08688 MMSL
4037164 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ozempic HUMAN PRESCRIPTION DRUG LABEL 1 0169-4132 INJECTION, SOLUTION 1.34 mg SUBCUTANEOUS NDA 20 sections
Ozempic HUMAN PRESCRIPTION DRUG LABEL 1 0169-4136 INJECTION, SOLUTION 1.34 mg SUBCUTANEOUS NDA 20 sections
RYBELSUS HUMAN PRESCRIPTION DRUG LABEL 1 0169-4303 TABLET 3 mg ORAL NDA 18 sections
RYBELSUS HUMAN PRESCRIPTION DRUG LABEL 1 0169-4307 TABLET 7 mg ORAL NDA 18 sections
RYBELSUS HUMAN PRESCRIPTION DRUG LABEL 1 0169-4314 TABLET 14 mg ORAL NDA 18 sections
Ozempic HUMAN PRESCRIPTION DRUG LABEL 1 70518-2143 INJECTION, SOLUTION 1.34 mg SUBCUTANEOUS NDA 19 sections